Pharmacology Made Easy: PCSK9 Monoclonal Antibody Inhibitors

A set of flashcards summarizing key concepts related to PCSK9 Monoclonal Antibody Inhibitors, specifically alirocumab, including its uses, administration, adverse reactions, and patient instructions.

PCSK9

Proprotein convertase subtilisin/kexin type 9, an enzyme made and secreted by liver cells that regulates the breakdown of LDL receptors.

LDL receptors

Receptors that help clear circulating LDL cholesterol from the blood by endocytosis.

Therapeutic Use of alirocumab

Decreases LDL cholesterol levels and is used for clients with known CHD or high risk for CHD, stroke, and unstable angina.

Adverse Drug Reactions of alirocumab

Includes vasculitis, angioedema, musculoskeletal pain, injection site reactions, and flu-like manifestations.

Administration method for alirocumab

Administer via subcutaneous injection using a prefilled pen or syringe, every two weeks or four weeks.

Client Instructions for alirocumab

Report serious hypersensitivity reactions, use correct administration technique, rotate injection sites, and perform a return demonstration.

Contraindications for alirocumab

Serious hypersensitivity reactions and latex allergies.

Monitoring requirements for alirocumab

Monitor lipid panel levels and for any serious hypersensitivity reactions.